Written by • 12:58 PM• Economics

Samsung Biologics’ follow-on share offering draws heavy demand in public subscription

Samsung Biologics reported unusually strong demand in the public subscription phase of its rights o…

Key Summary

  • Samsung Biologics completed the public subscription phase of its rights offering with demand far exceeding the shares offered.
  • For 71,854 unsold shares, the company received subscriptions for 9,745,071 shares, resulting in a subscription rate of 13,562.32%.
  • The cumulative subscription total, including employees, existing shareholders, and the public offering, reached 11,943,217 shares.
  • The company said the payment and refund date is November 17, and the new shares are scheduled to list on November 30.

Main Story

Samsung Biologics said its general public subscription for the unsold portion of a rights offering closed with strong demand. According to a disclosure filed with South Korea’s electronic disclosure system on the 16th, the company received subscriptions for 9,745,071 shares during the public offering period that ran from the 12th to the 13th.

The shares made available through the public subscription totaled 71,854 after the earlier shareholder subscription phase left that amount unallocated. That put the subscription rate at 13,562.32%, or 135.62-to-1 based on the number of shares offered.

The company said the overall rights offering had an intended issuance size of 2,270,000 shares. Employee stock ownership plan subscriptions accounted for 405,430 shares, while existing shareholders with subscription rights applied for 1,762,046 shares. Including 30,670 shares from over-subscription, the total number of shares subscribed before the public offering reached 2,198,146 shares, representing a 96.83% subscription rate for employees and existing shareholders combined.

When the public subscription is added, the cumulative number of subscribed shares came to 11,943,217, which corresponds to 526.13% of the planned issuance amount. Samsung Biologics also disclosed that the payment date and refund date are both set for the 17th, with the listing date for the newly issued shares scheduled for the 30th of the month.

Background

The supplied article provides transaction details for the share issuance and subscription process, but no broader background on the purpose of the capital increase or the company’s strategic plans was included.

Items Requiring Further Verification

  • The article reports subscription rates and cumulative totals from a company disclosure; those figures should be independently checked against the original filing.
  • The article states that payment and refund are scheduled for November 17 and the new share listing for November 30; these dates should be confirmed before publication if timing is critical.
Visited 1 times, 1 visit(s) today
Close Search Window
↑
Close